Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Matthew Langer Meyerson, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Matthew Meyerson and Todd Golub.
Connection Strength

2.485
  1. Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer. 2020 Feb; 1(2):235-248.
    View in: PubMed
    Score: 0.228
  2. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018 08; 560(7718):325-330.
    View in: PubMed
    Score: 0.207
  3. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
    View in: PubMed
    Score: 0.196
  4. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. Sci Transl Med. 2016 11 02; 8(363):363ra147.
    View in: PubMed
    Score: 0.183
  5. Genetic modifiers of EGFR dependence in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2014 Dec 30; 111(52):18661-6.
    View in: PubMed
    Score: 0.160
  6. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
    View in: PubMed
    Score: 0.135
  7. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
    View in: PubMed
    Score: 0.124
  8. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.115
  9. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20; 98(24):13790-5.
    View in: PubMed
    Score: 0.065
  10. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
    View in: PubMed
    Score: 0.058
  11. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2019 01; 565(7738):E5-E6.
    View in: PubMed
    Score: 0.053
  12. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292.
    View in: PubMed
    Score: 0.052
  13. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291.
    View in: PubMed
    Score: 0.052
  14. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690.
    View in: PubMed
    Score: 0.051
  15. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2017 12 11; 32(6):884.
    View in: PubMed
    Score: 0.049
  16. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60.
    View in: PubMed
    Score: 0.048
  17. High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell. 2016 08 08; 30(2):214-228.
    View in: PubMed
    Score: 0.045
  18. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
    View in: PubMed
    Score: 0.044
  19. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014 May; 32(5):479-84.
    View in: PubMed
    Score: 0.038
  20. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501.
    View in: PubMed
    Score: 0.038
  21. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
    View in: PubMed
    Score: 0.036
  22. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
    View in: PubMed
    Score: 0.036
  23. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012 May 20; 44(6):685-9.
    View in: PubMed
    Score: 0.034
  24. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
    View in: PubMed
    Score: 0.033
  25. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012 Mar 28; 483(7391):603-7.
    View in: PubMed
    Score: 0.033
  26. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
    View in: PubMed
    Score: 0.033
  27. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011 Dec; 1(7):608-25.
    View in: PubMed
    Score: 0.032
  28. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
    View in: PubMed
    Score: 0.032
  29. The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20.
    View in: PubMed
    Score: 0.031
  30. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19; 17(1):98-110.
    View in: PubMed
    Score: 0.029
  31. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8.
    View in: PubMed
    Score: 0.027
  32. Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A. 2008 Dec 23; 105(51):20380-5.
    View in: PubMed
    Score: 0.026
  33. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med. 2008 Aug; 14(8):822-7.
    View in: PubMed
    Score: 0.026
  34. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008 Feb 01; 68(3):664-73.
    View in: PubMed
    Score: 0.025
  35. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12.
    View in: PubMed
    Score: 0.025
  36. Comment on "The consensus coding sequences of human breast and colorectal cancers". Science. 2007 Sep 14; 317(5844):1500.
    View in: PubMed
    Score: 0.024
  37. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 2006 Dec 01; 66(23):11389-98.
    View in: PubMed
    Score: 0.023
  38. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 Jul 07; 436(7047):117-22.
    View in: PubMed
    Score: 0.021
  39. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.